Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
Crossref DOI link: https://doi.org/10.1007/s41669-017-0011-x
Published Online: 2017-01-30
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nazir, Jameel
Berling, Malin
McCrea, Charles
Fatoye, Francis
Bowditch, Sally
Hakimi, Zalmai
Wagg, Adrian
Funding for this research was provided by:
Astellas Pharma Europe Ltd
License valid from 2017-01-30